Jackson Square Partners LLC Sells 277,982 Shares of Stevanato Group S.p.A. (NYSE:STVN)

Jackson Square Partners LLC lowered its stake in Stevanato Group S.p.A. (NYSE:STVN) by 14.6% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,627,513 shares of the company’s stock after selling 277,982 shares during the quarter. Stevanato Group comprises about 3.8% of Jackson Square Partners LLC’s holdings, making the stock its 4th largest position. Jackson Square Partners LLC’s holdings in Stevanato Group were worth $35,464,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of STVN. Van Berkom & Associates Inc. acquired a new position in Stevanato Group in the 4th quarter worth $39,000. PNC Financial Services Group Inc. lifted its stake in shares of Stevanato Group by 1,457.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 5,654 shares of the company’s stock worth $123,000 after acquiring an additional 5,291 shares in the last quarter. US Bancorp DE lifted its stake in shares of Stevanato Group by 17.9% in the fourth quarter. US Bancorp DE now owns 8,527 shares of the company’s stock worth $186,000 after acquiring an additional 1,295 shares in the last quarter. Marco Investment Management LLC purchased a new position in Stevanato Group in the fourth quarter valued at about $203,000. Finally, Hardy Reed LLC grew its stake in Stevanato Group by 8.2% during the 3rd quarter. Hardy Reed LLC now owns 11,077 shares of the company’s stock valued at $222,000 after purchasing an additional 840 shares in the last quarter.

Analyst Ratings Changes

Several equities analysts have recently commented on STVN shares. Wolfe Research began coverage on Stevanato Group in a research note on Friday, December 13th. They set an “outperform” rating and a $28.00 target price for the company. Morgan Stanley reissued an “equal weight” rating and issued a $23.00 target price (down previously from $24.00) on shares of Stevanato Group in a research report on Tuesday, December 3rd. William Blair reiterated an “outperform” rating on shares of Stevanato Group in a research note on Friday, March 7th. Bank of America boosted their price objective on Stevanato Group from $24.00 to $26.00 and gave the company a “buy” rating in a report on Friday, December 13th. Finally, UBS Group decreased their target price on Stevanato Group from $24.00 to $23.50 and set a “neutral” rating for the company in a research report on Friday, March 7th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, Stevanato Group currently has an average rating of “Moderate Buy” and an average target price of €27.75 ($29.84).

Stevanato Group Trading Down 0.8 %

NYSE:STVN opened at €22.34 ($24.02) on Tuesday. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.81 and a quick ratio of 1.21. The firm has a market capitalization of $6.77 billion, a P/E ratio of 47.53, a P/E/G ratio of 7.18 and a beta of 0.60. Stevanato Group S.p.A. has a 12-month low of €16.56 ($17.81) and a 12-month high of €33.49 ($36.01). The business has a 50 day simple moving average of €21.04 and a 200 day simple moving average of €20.59.

Stevanato Group (NYSE:STVN) last posted its earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of €0.20 ($0.22). Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The firm had revenue of €352.68 million during the quarter, compared to analyst estimates of €346.26 million. Equities research analysts predict that Stevanato Group S.p.A. will post 0.5 EPS for the current year.

Stevanato Group Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.